Sign in
WithdrawnPhase 1

Mesenchymal Stromal Cells for COVID-19 and Viral Pneumonias

Key facts

Who runs it
Medical University of South Carolina
Where
Charleston, United StatesSee the site
Trial code
Status
Withdrawn
Phase
Phase 1
Started
1 Oct 2024
Ended
1 Oct 2024
Type of study
Interventional
Treatments tested
  • Allogeneic Mesenchymal Stromal Cells
Record updated
30 October 2024
Why it stopped
Funding

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 24 criteriaShow less

Who can take part

  • Hospitalized with COVID-19 respiratory symptoms and confirmation via COVID-19 SARS-CoV-2 RT-PCR testing
  • Patient or their surrogate is willing and able to provide written informed consent and comply with all protocol requirements
  • Diagnosis with Mild or Moderate Pneumonia not requiring mechanical ventilation: Patient must have at least one of the following features:; Bilateral pneumonia present on chest radiograph or computed tomography ii. Partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) on arterial blood gas showing: >100mmHg and ≤ 300mmHg regardless of oxygen dose at time of testing; Pulse oxygen saturation (SpO2) at rest ≤ 93% or any degree of hypoxia requiring supplemental oxygen
  • Patient agrees to storage of specimens for future testing
  • Willingness to undergo mechanical ventilation for worsening

Who cannot take part

  • Intubation with mechanical ventilation prior to study enrolment. High flow nasal cannula and non-invasive mechanical ventilation is allowed
  • History of long-term use of immunosuppressive agents including prednisone dose >5mg daily over the 30 days prior to enrollment
  • Obstructive pneumonia induced by lung cancer or other known causes
  • Significant comorbid illness likely to impact the outcome of COVID-19 including but not limited to active malignancy other than skin cancer
  • History of severe chronic respiratory disease and requirement for long-term oxygen therapy
  • History of moderate and severe liver disease (Child-Pugh score >12)
  • History of deep venous thrombosis, pulmonary embolism, cerebral vascular disease within the last 3 years
  • Known HIV, hepatitis virus, or syphilis infection
  • Co-Infection of tuberculosis, influenza virus, adenovirus and other respiratory infection virus
  • Allergy to diphenhydramine, or hydrocortisone
  • Any condition unsuitable for the study as determined by the investigators
  • Receipt of experimental therapy for COVID-19 with the exception of convalescent plasma, dexamethasone or another corticosteroid, or remdesivir in an open label study
  • Estimated or actual rate of creatinine clearance < 15 ml/min
  • Pneumonia caused by bacteria, mycoplasma, chlamydia, legionella, fungi or other viruses
  • Patients who are participating in other therapeutic clinical trials within 30 days of consent
  • Undergoing hemodialysis or peritoneal dialysis
  • Substance abuse sufficient that the patient is unlikely to comply with testing requirements
  • Moribund patient not expected to survive > 24hours
  • Female subjects with positive pregnancy test, breastfeeding, or planning to become pregnant/breastfeed during the study period

Where in United States

  • Medical University of South CarolinaCharleston, United States

About the trial

What the trial wants to find out

This is an open-label phase 1 clinical trial of allogeneic umbilical cord derived mesenchymal stromal cells (MSCs) for hospitalized individuals with COVID-19 or other viral pneumonias. Hospitalized individuals who are within 7 days of the onset of a viral pneumonia will be given 2 doses of MSCs at days 1 and 3 after consent. The safety of intravenous infusion will be tested and course of the oxygen response to treatment over 90 days will be evaluated.

The group in the trial

  • Allogeneic Mesenchymal Stromal Cell infusionTreatment being tested

    Intravenous infusion of 1.25-1.5 x 10\^6 cells/kg with a maximal dose of 100 x 10\^6 cells on days 1 and 3 after study enrollment.

    Treatment: Allogeneic Mesenchymal Stromal Cells

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Safety and Tolerability of Allogeneic Umbilical Cord Derived Mesenchymal Stromal Cells (UC-MSCs) to Limit COVID Associated ComplicatioNs: an Open Label, Phase 1 Study in Hospitalized Patients (SAMPSON-1)
Record updated
30 October 2024